CLAIM CARD
The corpus contains a pronounced mechanism-to-clinic gap: cell-level and animal-model evidence for DDW's anticancer and metabolic mechanisms is relatively rich, but corresponding clinical-effectiveness data are sparse. Similarly, DDW-induced GLUT4 translocation and a reported three- to four-fold increase in glucose uptake under insulin-resistant conditions (Kondo 2024) have not been validated against hard cardiometabolic endpoints such as HbA1c reduction toward the 7% target recommended by ADA 2024. Long-term safety data, dose–response characterization in humans, and quality-of-life outcomes are entirely absent from the curated references. Until controlled trials bridge these mechanistic observations to patient-centered endpoints, the therapeutic promise of deuterium-depleted water remains plausible but unproven.
Evidence grade: exploratory
Contradiction status: none
Publication: d8263221-9f0a-41ec-95ec-4711d2e47db6
Provenance: Derivation Web chain
Citation Support
source_1Somlyai 2025source_2Somlyai 2023source_3Boros 2021source_4Korchinsky 2024source_5Molnar 2021